Summary
Abiomed is not a very well-known medical tech stock.
ABMD has performed extremely well and is poised to double or triple in next 5 years.
ABMD has great financial leverage and a strong MOAT.
ABMD could be the next ISRG in the making.
Editor's note: Seeking Alpha is proud to welcome Rajesh Kumar as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Investment thesis
Abiomed (ABMD), a provider of percutaneous coronary intervention (PCI) devices, is a name to start adding to your portfolio because of its expanding addressable market, fantastic execution, and excellent operating leverage.
